Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05027997
Other study ID # ADX48621-203
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 6, 2021
Est. completion date December 2021

Study information

Verified date November 2021
Source Addex Pharma S.A.
Contact Study Director
Phone 877-409-1775
Email Clinical.Team@addexpharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to assess the safety and tolerability of dipraglurant in patients with blepharospasm (BSP) (randomized 1:1:1 to receive dipraglurant 50 mg, 100 mg or placebo) and explore the efficacy of 50 mg and 100 mg immediate release tablets (versus placebo) on the severity and frequency of BSP signs and symptoms using objective measures, clinical ratings and patient reported outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date December 2021
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Patients with an established diagnosis of idiopathic benign essential blepharospasm - Must have had prior response to to botulinum toxin (BoNT) reported on last 2 consecutive injection cycles - Last injection of BoNT at least 8 weeks prior to Screening assessments - Patient is experiencing features of Blepharospasm (BSP) of moderate severity/frequency at study entry. Exclusion Criteria: - BSP that is known or suspected to be associated with a known cause such as neuroleptic exposure, brain injury or lesion, stroke, Parkinson's disease, or related Parkinsonisms - History of surgical intervention (e.g., deep brain stimulation) or orbital myectomy for dystonia - Disabling eyelid opening apraxia - Other neurological disease (including psychiatric disease and/or cognitive impairment) that, in the opinion of the investigator, would affect the patient's ability to complete study assessments. - Other significant medical condition that may affect the safety of the patient or preclude adequate participation in the study. Other protocol-defined inclusion and exclusion criteria may apply

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dipraglurant
Oral tablet
Placebo
Oral matching placebo tablet

Locations

Country Name City State
United States Emory University Atlanta Georgia

Sponsors (1)

Lead Sponsor Collaborator
Addex Pharma S.A.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability of dipraglurant as measured by incidence of adverse events The primary outcome will be testing the safety and tolerability of dipraglurant in patients with blepharospasm based on the incidence of adverse events reported by patients and/or as identified by the Investigator based on clinical assessments conducted during the study. Baseline to Day 2
Primary Computerized Motor Objective Rater (CMOR) analysis of blinking activity Video analysis, by an independent rater, of the mean proportion of eye closure time, severity of periocular spasms, and blink rate. Decreased eye closure time, severity of periocular spasms and blink rate indicates improvement of blepharospasm symptoms. Baseline to Day 2
Primary Skintronics wearable analysis of blinking activity Analysis of blinking activity as recorded on the Skintronics wearable device. Decreased blink activity indicates improvement of blepharospasm symptoms. Baseline to Day 2
Secondary Jankovic Rating Scale (JRS) severity score The JRS is a clinician rated scale for blepharospasm. The intensity of eyelid spasms is measured based on a 5 point grading system where 0 indicates no symptoms and 4 indicates the most severe symptoms. Baseline to Day 2
Secondary Jankovic Rating Scale (JRS) frequency score The JRS is a clinician rated scale for blepharospasm. The frequency of eyelid spasms is measured based on a 5 point grading system where 0 indicates no symptoms and 4 indicates highest frequency symptoms. Baseline to Day 2
Secondary Global Dystonia Severity Rating Scale (GDS) The GDS is a clinician rated scale for the assessment of dystonia severity across multiple body regions. Each body region is rated on a scale from 0-10 where 0 represents no dystonia and 10 represents severe dystonia. Baseline to Day 2
Secondary Blepharospasm Phenotyping Tool (BPT) The BPT is a clinician rated scale assessing 4 major phenotypic elements of blepharospasm using a 4 point scale for severity and frequency, where 0 indicates no symptoms and 4 indicates the highest frequency and/or most severe symptoms. Baseline to Day 2
Secondary Blepharospasm Severity Rating Scale (BSRS) The BSRS is a clinician rated scale for rating severity of blepharospasm based on 6 clinical features of the condition. A total score is generated based on the combined score for severity and frequency and where a higher value indicates more severe symptoms. Baseline to Day 2
Secondary Clinician's Global Impression of Severity (CGI-S) score The CGI-S score is used by the Investigator to determine, in a global sense, how severe the patients blepharospasm is in the context of other blepharospasm patients. Increased scores indicate more severe symptoms. Baseline to Day 2
Secondary Blepharospasm Disability Index (BSDI) The BSDI is a 6 item patient rated disability scale that measures how blepharospasm effects activities of daily living. Each item is scored on a 5 point scale to produce a total score of up to 30, where a higher individual item score and a higher total score indicate greater disability to the patient. Baseline to Day 2
Secondary Patient Global Impression of Change (PGI-C) score The PGI-C score is a patient reported outcome that assesses how much the blepharospasm symptoms have improved or worsened. A score of 0 indicates no change, negative scores down to -3 indicate worsening, and positive scores of up to 3 indicate improvement. Baseline to Day 2
See also
  Status Clinical Trial Phase
Completed NCT01433757 - Ampicillin for DYT-1 Dystonia Motor Symptoms Phase 1
Recruiting NCT00971854 - Alteration of Deep Brain Stimulation Parameters for Dystonia N/A
Enrolling by invitation NCT00355927 - Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders. N/A
Completed NCT00169338 - Pallidal Stimulation in Patients With Post-anoxic and Idiopathic Dystonia Phase 2
Completed NCT00004421 - Deep Brain Stimulation in Treating Patients With Dystonia Phase 2/Phase 3
Terminated NCT03270189 - Effect of the Visual Information Change in Functional Dystonia N/A
Recruiting NCT02583074 - Clinical Trial of STN-DBS for Primary Cranial-Cervical Dystonia N/A
Recruiting NCT06117020 - Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals Phase 1
Completed NCT01432899 - Studying Childhood-Onset Hemidystonia
Completed NCT04948684 - Efficacy of Botulinum Toxin for the Treatment of Dystonia Associated With Parkinson's Disease and Atypical Parkinsonism
Completed NCT05106816 - The Effects of Vibrotactile Stimulation in Patients With Movement Disorders N/A
Completed NCT00465790 - Research of Biomarkers in Parkinson Disease Phase 0
Active, not recruiting NCT00142259 - Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia Phase 4
Recruiting NCT05663840 - Effects of Exercise on Dystonia Pathophysiology N/A
Not yet recruiting NCT06038097 - Efficacy and Safety of Radiofrequency Pallidotomy in the Management of Dystonia N/A
Recruiting NCT04286308 - Cortical-Basal Ganglia Speech Networks N/A
Active, not recruiting NCT03582891 - The Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy N/A
Completed NCT03318120 - Exercise Training in Dystonia N/A
Completed NCT04568681 - Deep Brain Stimulation Effects in Dystonia
Active, not recruiting NCT05956223 - The Development of a System for Measurement of Tremor N/A